Recent Company News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Company presented positive preliminary data from Phase 1 dose escalation portion of

-- $7.0 million in third quarter LUMRYZ™ net revenue from U.S. commercial launch -- -- Generated robust demand for LUMRYZ with greater than 1,000 patients enrolled in RYZUPTM and more than 400 patients initiating therapy as of September 30 -- -- LUMRYZ to be added to preferred position for CVS commercial formularies effective January 1, 2024 -- -- Submitted sNDA for LUMRYZ in pediatric narcolepsy population on November 7th -- -- Management to host a conference call today at 8:30 a.m. ET -- DUBLI

-- Successfully commenced U.S. commercial launch of LUMRYZ™-- -- Received final FDA approval for LUMRYZ with orphan drug exclusivity granted through May 1, 2030 -- -- Significant early progress on payor coverage, prescriber certifications and patient enrollments -- -- Management to host a conference call today at 8:30 a.m. ET -- DUBLIN, Ireland, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform

• LUMRYZ NDA amendment filed March 1 requesting FDA final approval • Received FDA authorization to import LUMRYZ in advance of final approval decision; shortens timeline between potential approval and

Conference Call Wednesday March 29, 2023 at 4:30 p.m. ET...